Pediatric Drug Development

26 May

Pediatric drug development is now a core regulatory requirement in both the US and EU. It’s also one of the most complex areas to get right—scientifically, operationally, and strategically.

Why pediatric strategy needs expert support

Regulators no longer accept “we’ll think about children later.” In both regions:

  • Pediatric plans must be defined early (iPSP in the US, PIP in the EU).
  • Requirements are mandatory for most new products (with limited exemptions).

Missteps can lead to:

  • Delayed adult approvals or submissions
  • Loss or deferral of exclusivity incentives
  • Duplicative or under‑powered studies
  • Difficult (and public) regulatory negotiations

You need to convert these obligations into a coherent, proactive program rather than a late‑stage compliance scramble.

What could a consultant do for you?

1. Global pediatric strategy and gap assessment

  • Assess where your asset stands versus US/EU pediatric requirements:
  • Does the indication occur in children? In which age groups?
  • How do existing treatments and unmet needs shape expectations?
  • What pediatric obligations are likely under PREA (US) and the EU Pediatric Regulation?
  • Map your current and planned adult program against:
    • iPSP timing (US)
    • PIP timing (EU, including PDCO review cycles)
  • Identify:
    • Opportunities for extrapolation and streamlined programs
    • Areas of high regulatory risk or feasibility concern
    • Where incentives (BPCA, SPC extension, orphan incentives) can be leveraged

Your outcome should be a concise strategy document outlining pediatric obligations, options, risks, and a high‑level global plan that integrates with your adult development and commercial timelines.

 

2. US Pediatric Study Plan (iPSP) design and negotiation

Develop a scientifically robust, regulator‑ready initial Pediatric Study Plan (iPSP):

  • Justification for included/excluded age groups
  • Overall pediatric development concept (PK/PD, dose‑finding, efficacy, safety)
  • Proposed use of modelling & simulation and data extrapolation
  • Waiver and deferral requests, with supporting rationale
  • Coordinate and support FDA interactions:
  • Background packages for FDA Type B meetings (e.g., End‑of‑Phase 2)
  • Briefing documents with focused questions and clear positions
  • Written responses and negotiation strategies following FDA feedback
  • Align iPSP deliverables with global clinical and regulatory plans to avoid duplication with EU requirements.

Your outcome should be an agreed iPSP that satisfies PREA, fits your adult program, and minimizes unnecessary pediatric burden, with a clear understanding of what is expected pre‑ and post‑approval.

 

3. EU Pediatric Investigation Plan (PIP) strategy, drafting, and PDCO interaction

Design your Pediatric Investigation Plan (PIP) to be:

  • Scientifically sound
  • Operationally feasible
  • Strategically aligned with US plans
  • Prepare and manage the full PIP lifecycle:
    • Pre‑submission discussions with EMA/PDCO where appropriate
  • Drafting the PIP dossier, including:
    • Target populations and age subsets (including neonates where relevant)
    • Study designs and endpoints aligned with evolving EU standards
    • Formulation development plans and excipient justification
    • Waiver and partial waiver arguments
    • Deferral proposals and timelines
  • Handling PDCO questions, oral explanations, and negotiations
  • Preparing and managing PIP modifications as the program evolves

Your outcome should be an  agreed PIP that:

  • Meets Pediatric Regulation requirements
  • Protects or enhances your incentive package (SPC extension / orphan incentives)
  • Is realistically executable and synchronized with your adult development milestones.

 

4. Integrated US–EU pediatric program alignment

You should aim to :

  • Build a single, global pediatric development framework that underpins both iPSP (US) and PIP (EU)
  • Align core elements across regions:
    • Study protocols (global where possible)
    • Age cohorts and staging of enrolment
    • Endpoints and assessment schedules
    • PK/PD strategies and exposure‑response modelling
    • Identify where regional differences are unavoidable (e.g., labelling conventions, specific PDCO vs FDA preferences) and manage them proactively.

Your outcome should be a harmonized global pediatric plan that:

  • Minimizes re‑work and conflicting study demands
  • Uses each patient enrolled as efficiently as possible
  • Simplifies internal execution for clinical and operations teams

  1. Pediatric formulations and feasibility support

To make the items above happen, your consultant should

  • Incorporate pharmaceutical and clinical practicality into pediatric planning:
  • Review suitability of the existing formulation for different age groups
  • Identify need for age‑appropriate dosage forms (e.g., oral liquids, mini‑tablets, dispersible tablets)
  • Highlight excipient constraints (e.g., in neonates/infants)
  • Work with your technical and clinical teams to ensure:
    • Formulation timelines align with PIP/iPSP milestones
    • Study designs reflect real‑world feasibility (palatability, dose volume, administration routes)
  • Advise on site and network strategies to improve pediatric recruitment and compliance.

Your outcome should be pediatric plans that can actually be delivered—backed by realistic assumptions about formulation readiness and recruitment practicality.

 

6. Extrapolation, modelling & simulation, and innovative design support

Your chosen consultant should:

  • Help you leverage regulatory openness to modern approaches:
    • Extrapolating efficacy from adults to pediatrics, or older to younger age groups, where justified
    • Using population PK/PD, physiologically‑based PK (PBPK), and exposure–response modelling
  • Designing efficient adaptive or Bayesian pediatric trials
  • Position these approaches clearly in:
    • iPSP and PIP documents
    • Regulatory briefing materials
    • Responses to agency questions

Your outcome should be lean, scientifically credible pediatric programs that reduce unnecessary patient exposure and focus on the data that truly influence benefit–risk and labelling.

 

7. Lifecycle management: Amendments, post‑approval studies, and labelling

Your consultant can assist to:

  • Manage pediatric commitments over time:
    • PIP modifications as data, feasibility, or standards of care change
    • PREA post‑marketing requirements (PMRs) and BPCA Written Requests
  • Translate pediatric data into labelling:
    • US Prescribing Information and EU SmPC pediatric sections
    • Presentation of negative or inconclusive data in a way that is clear, balanced, and compliant
  • Support internal governance:
    • Scenario planning for delayed or failed pediatric studies
    • Impact assessment on exclusivity, access, and payer expectations

Your outcome should be a controlled, predictable pediatric lifecycle that supports your long‑term regulatory and commercial strategy, rather than undermining it with late surprises.

 

When to use a consultant

Using a consultant is particularly effective when:

  • You are entering Phase 2 and need to understand iPSP and PIP implications before pivotal adult trials.
  • You are a small or mid‑size biotech without in‑house pediatric regulatory specialists.
  • You have a complex or novel mechanism (e.g., oncology, gene/ cell therapies, targeted therapies) where pediatric expectations are less straightforward.
  • You are considering global development and need an integrated US–EU pediatric strategy, not two separate regional plans.

 

Sharp Regulatory Consulting supports companies in navigating this complexity by designing and executing integrated US/EU pediatric strategies that are compliant, efficient, and aligned with business goals.

News

Related posts